See more : Crystal International Group Limited (2232.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Biocept, Inc. (BIOC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biocept, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Gresham House Renewable Energy VCT 1 plc (GV1A.L) Income Statement Analysis – Financial Results
- Koala Corporation (KARE) Income Statement Analysis – Financial Results
- Unisync Corp. (USYNF) Income Statement Analysis – Financial Results
- Alcanna Inc. (CLIQ.TO) Income Statement Analysis – Financial Results
- Impex Ferro Tech Limited (IMPEXFERRO.NS) Income Statement Analysis – Financial Results
Biocept, Inc. (BIOC)
About Biocept, Inc.
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.86M | 61.25M | 27.46M | 5.53M | 3.25M | 5.07M | 3.22M | 609.91K | 133.42K | 134.25K | 109.29K | 1.05K |
| Cost of Revenue | 28.44M | 37.76M | 21.34M | 10.98M | 10.05M | 9.35M | 6.92M | 4.60M | 2.17M | 2.33M | 1.20M | 17.32K |
| Gross Profit | -2.58M | 23.49M | 6.12M | -5.45M | -6.80M | -4.28M | -3.70M | -3.99M | -2.04M | -2.20M | -1.09M | -16.27K |
| Gross Profit Ratio | -9.99% | 38.34% | 22.30% | -98.56% | -209.26% | -84.37% | -114.70% | -653.58% | -1,526.91% | -1,635.56% | -999.56% | -1,546.58% |
| Research & Development | 6.16M | 4.96M | 5.22M | 4.70M | 4.47M | 3.36M | 2.71M | 2.86M | 4.50M | 3.09M | 6.56M | 8.85M |
| General & Administrative | 16.11M | 12.61M | 9.97M | 6.97M | 7.07M | 7.19M | 6.56M | 5.69M | 5.20M | 2.51M | 2.06M | 2.73M |
| Selling & Marketing | 7.13M | 8.32M | 6.40M | 5.94M | 5.91M | 6.34M | 5.05M | 3.88M | 2.14M | 148.90K | 785.32K | 672.93K |
| SG&A | 23.24M | 20.93M | 16.37M | 12.91M | 12.99M | 13.53M | 11.61M | 9.57M | 7.34M | 2.66M | 2.85M | 3.40M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 29.40M | 25.89M | 21.59M | 17.61M | 17.46M | 16.90M | 14.33M | 12.42M | 11.84M | 5.75M | 9.41M | 12.25M |
| Cost & Expenses | 57.84M | 63.66M | 42.93M | 28.59M | 27.51M | 26.24M | 21.25M | 17.02M | 14.01M | 8.08M | 10.61M | 12.27M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 316.00K | 290.00K | 2.34M | 2.08M | 310.98K | 0.00 | 0.00 | 0.00 | 0.00 | 2.07M | 0.00 | 0.00 |
| Depreciation & Amortization | 1.66M | 2.64M | 1.00M | 773.31K | 800.91K | 575.72K | 322.03K | 261.41K | 251.20K | 266.55K | 365.57K | 369.31K |
| EBITDA | -30.33M | -2.41M | -15.47M | -23.06M | -24.26M | -21.17M | -18.03M | -16.41M | -13.87M | -7.68M | -10.57M | -12.24M |
| EBITDA Ratio | -117.29% | -3.93% | -56.33% | -417.05% | -746.35% | -417.76% | -559.25% | -2,690.70% | -10,399.07% | -5,719.30% | -9,671.01% | -1,163,859.41% |
| Operating Income | -31.98M | -2.41M | -15.47M | -23.06M | -24.26M | -21.17M | -18.03M | -16.41M | -13.87M | -7.94M | -10.50M | -12.27M |
| Operating Income Ratio | -123.69% | -3.93% | -56.33% | -417.05% | -746.35% | -417.76% | -559.25% | -2,690.70% | -10,399.07% | -5,917.86% | -9,610.37% | -1,166,444.49% |
| Total Other Income/Expenses | -229.00K | -290.00K | -2.34M | -2.08M | -310.98K | -431.41K | -372.23K | -537.12K | -1.99M | -1.29M | -1.76M | -1.36M |
| Income Before Tax | -32.21M | -2.70M | -17.81M | -25.14M | -24.57M | -21.61M | -18.40M | -16.95M | -15.86M | -9.23M | -12.26M | -13.63M |
| Income Before Tax Ratio | -124.57% | -4.41% | -64.84% | -454.69% | -755.92% | -426.27% | -570.79% | -2,778.76% | -11,891.12% | -6,877.26% | -11,216.80% | -1,295,483.46% |
| Income Tax Expense | -125.00K | 125.00K | -764.58K | -523.33K | 1.89K | 7.62K | 2.05K | 1.61K | 1.51K | 800.00 | 800.00 | 800.00 |
| Net Income | -32.09M | -2.82M | -17.04M | -24.61M | -24.57M | -21.61M | -18.40M | -16.95M | -15.87M | -9.23M | -12.26M | -13.63M |
| Net Income Ratio | -124.09% | -4.61% | -62.06% | -445.23% | -755.98% | -426.42% | -570.86% | -2,779.03% | -11,892.25% | -6,877.86% | -11,217.53% | -1,295,559.51% |
| EPS | -56.78 | -5.73 | -43.16 | -357.54 | -2.63K | -7.07K | -17.29K | -23.28K | -96.74K | -55.29K | -73.41K | -81.61K |
| EPS Diluted | -56.78 | -5.73 | -43.16 | -357.41 | -2.63K | -7.07K | -17.29K | -23.28K | -96.74K | -55.29K | -73.41K | -81.61K |
| Weighted Avg Shares Out | 565.13K | 492.53K | 394.84K | 68.85K | 9.33K | 3.06K | 1.06K | 728.00 | 164.00 | 167.00 | 167.00 | 167.00 |
| Weighted Avg Shares Out (Dil) | 565.13K | 492.53K | 394.84K | 68.87K | 9.33K | 3.06K | 1.06K | 728.00 | 164.00 | 167.00 | 167.00 | 167.00 |
Biocept to use CNSide assay in study looking at biomarkers in patients with metastatic breast cancer
Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System
Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System
Biocept continuing to position itself as 'leader in neurological tumor diagnostics' as it posts second quarter results
Biocept Reports Second Quarter 2022 Financial Results
Biocept Reports Second Quarter 2022 Financial Results
Biocept expands availability of its CNSide assay for most cancers that metastasize to the central nervous system
Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System
Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
Source: https://incomestatements.info
Category: Stock Reports